Global Biosimilar Markets: Europe vs United States - How Regulatory Paths Shape Adoption and Cost Savings
Europe led the world in biosimilar adoption with clear regulations and hospital procurement policies. The U.S. lagged due to legal barriers - until 2024, when the FDA removed key hurdles. Now, both markets are accelerating, driving down costs for life-saving biologic drugs.
CONTINUE